Diversity in clinical trials has long been a challenge in medicines development. Too often, women, ethnic minorities, and individuals from lower socioeconomic backgrounds have been excluded — resulting in mistrust, data gaps, and inequities in healthcare outcomes.

As part of Module 3: Drug Discovery, Exploratory and Confirmatory Development, CMD students from across Europe and Asia tackled this issue head-on. Using Edward de Bono’s Six Thinking Hats method, they analyzed the problem of diversity from multiple perspectives, underscoring both the urgency of change and the opportunities ahead.

The Problem of Exclusion

Historically, the exclusion of underrepresented groups has undermined both science and trust. As one participant reflected:

“Historically, diversity in clinical trials has been challenging. The lack of inclusion of women, ethnic minorities, and people from lower socioeconomic backgrounds has led to mistrust in clinical research—even until today.” – Mariel Morales Sahm, Pfizer (Germany)

This mistrust still shapes how many communities perceive clinical research, underscoring the need for proactive measures to rebuild confidence.

The Patient Perspective

The group highlighted that patients’ emotions often reflect their lived experiences with research. Feelings of fear, anger, and distrust were common themes.

“Patients often feel fear, anger, or distrust when excluded from clinical research. To alleviate this, we must make information clear, build therapeutic relationships, and debunk misconceptions to restore confidence.” – William Greenwood, Pfizer (France)

By centering the patient voice, CMD students recognized that inclusivity is not just about numbers — it’s about building relationships, communication, and respect.

The Benefits of Inclusion

Scientific evidence is clear: diverse trials produce better, more generalizable data. Including broader populations helps reveal genetic and environmental factors that affect how medicines work, reduces health disparities, and strengthens trust in outcomes.

As one group member noted:

“By including diverse patient populations, we can develop treatments that are more tailored, safer, and more effective—improving trust in data and reducing health disparities.” – Olivia Strasser, Pfizer (Austria)

Toward Solutions

The students outlined innovative solutions to improve trial diversity:

  • AI-powered recruitment platforms to identify and reach underrepresented patients.
  • Flexible trial designs, including virtual participation, culturally sensitive materials, and logistical support (transportation, childcare).
  • Community collaboration through partnerships with local leaders and organizations to build trust and awareness.

Together, these strategies point to a more equitable and effective future for clinical research.

Why This Matters

By engaging with real-world challenges in Module 3: Drug Discovery, Exploratory and Confirmatory Development, CMD students aren’t just studying theory — they are preparing to become leaders who drive systemic change in medicines development. Their project shows how today’s learners can shape tomorrow’s clinical landscapes: more inclusive, more representative, and ultimately, more trusted.

Advance Your Career in Medicines Development

🌍 Applications are now open for the 2026 CMD Program cohort!

Whether you aim to complete the full Certification in Medicines Development or prefer to take individual modules, CMD offers a flexible, globally recognized pathway to grow as a leader in pharmaceutical medicine.

📅 The 2026 CMD Program begins in January 2026.
🔗 Learn more and apply today: https://info.gmdpacademy.org/gmdpapplication

Join professionals from more than 85 countries in shaping the future of medicines development.

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred